top of page

The Science

Willis RE. Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. International Journal of Molecular Sciences. 2016; 17(9):1552. https://doi.org/10.3390/ijms17091552

Vital Oncogenes are not the typical oncogenes routinely targeted by pharmaceutical companies. ONCOVA's Bioinformatic platform reveals these to be non-protein kinase entities with distinct and unique characteristics - described below.

​

ONCOVA BIOSCIENCES has identified over 150 targets of interest. Each has some or all of the required Vital Oncogene characteristics. Approximately 100 fulfill stringent criteria. Approximately 75 fulfill stringent criteria and have significant evidenced-based supportive literature.

​

Vital Oncogenes are mutated, fused gene regulators with all of the properties that distinctly indicate their capacity to initiate and propagate oncogenesis. This makes them the ideal candidates for potent, efficatious, less toxic, uniquely specific targeted cancer therapy.

Oncogenic Characteristics

  • IT IS A  MULTI-DOMAIN PHOSPHOPROTEIN TRANSCRIPTION ACTIVATOR

  • IT IS AN INTRINSICALLY DISORDERED PROTEIN

  • IT HAS A CHARACTERISTIC ACTIVATING MUTATION (FUSED PROTEIN)

  • IT HAS A DEMONSTRATED CANCER ASSOCIATION

  • ITS MOLECULAR MECHANISM OCCURS DIRECTLY WITHIN THE NUCLEUS

  • ITS ONCOPROTEIN PRODUCT IS FUNCTIONALLY UPSTREAM FROM ITS ASSOCIATED CELLULAR PATHWAYS

  • ITS ONCOPROTEIN PRODUCT MUST USURP OR ALTER NORMAL CELL CYCLE CONTROL MECHANISMS

  • THERE MUST BE CLINICAL EVIDENCE OF ONCOGENE ADDICTION

  • IT IS PROMOTER PROMISCUOUS

  • IT FUNCTIONS BY PROTEIN-PROTEIN INTERACTIONS

  • THERE IS A CRUCIAL COMMON MECHANISTIC EVENT INVOLVING ITS PROTEIN-PROTEIN INTERACTION.

bottom of page